Context Therapeutics Inc. (CNTX) Stock Ticker
Market factors today
Unlock the full CNTX picture
About Context Therapeutics Inc.
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
CNTX stock facts
| Ticker symbol | CNTX |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $31.8M |
| CEO | Martin A. Lehr |
| Employees | 15 |
| Headquarters | Philadelphia, PA, US |
| IPO date | 2021-10-20 |
| Website | www.contexttherapeutics.com |
What you can see for CNTX on Tickr
Live CNTX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the CNTX report.
Rankings
FAQ
What is the ticker symbol for Context Therapeutics Inc.?
The ticker symbol for Context Therapeutics Inc. is CNTX, listed on the NASDAQ.
What is CNTX?
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the…